EMA: generally no product-specific GLs [Regulatives / Guidelines]
❝ If you succeed in convincing MHRA that spironolactone is a pro-drug, you would have to show BE only for one metabolite (active or not). I would opt for canrenone.
Good morning Helmut,
I'm not sure if I picked up some decaf by mistake this morning or I'm still hungover from a Thrusday night binge, but this bit above doesn't look quite right to me. According to the guideline:
Also for inactive prodrugs, demonstration of bioequivalence for parent compound is recommended. The active metabolite does not need to be measured.
So, if spironolactone can indeed be measured, I'm not sure it matters whether it's a prodrug or not. Did I miss something?

Torn
Complete thread:
- Bioequivalence Recommendations for Specific Products cr.maroj 2013-09-19 11:00
- Bioequivalence Recommendations for Specific Products Ohlbe 2013-09-19 11:45
- EMA: Draft product-specific guidances ♬ Helmut 2013-11-15 15:45
- EMA: Draft product-specific guidances ♬ luvblooms 2013-11-19 06:35
- EMA: Capecitabine product-specific guidance ♬ mittyri 2013-12-10 15:33
- EMA: Capecitabine product-specific guidance ♬ Helmut 2013-12-10 16:11
- Russian GL 2013: harmonisation to EMA mittyri 2013-12-14 11:57
- EMA: Capecitabine product-specific guidance ♬ Helmut 2013-12-10 16:11
- EMA: Draft product-specific guidances ♬ pash413 2013-12-18 12:35
- EMA: Use of AUC72 not dependent on t½ Helmut 2013-12-18 14:35
- End of consultation approaching‼ Helmut 2014-02-10 18:33
- End of consultation approaching‼ Dr_Dan 2016-01-28 09:27
- Guesstimates Helmut 2016-01-28 13:32
- End of consultation approaching‼ Dr_Dan 2016-01-28 09:27
- EMA: Draft product-specific guidances ♬ Helmut 2013-11-15 15:45
- EMA: generally no product-specific GLs Helmut 2013-09-19 11:48
- Thank you cr.maroj 2013-09-19 13:03
- EMA: generally no product-specific GLsThe Outlaw Torn 2013-09-20 07:52
- EMA: parent whenever possible Helmut 2013-09-20 09:02
- EMA: parent whenever possible cr.maroj 2013-09-20 10:14
- EMA: parent whenever possible Helmut 2013-09-20 12:53
- EMA: parent whenever possible Ohlbe 2013-09-20 13:52
- EMA: parent whenever possible mittyri 2013-09-20 14:55
- EMA vs. Russia Helmut 2013-09-20 19:21
- FDA: Prasugrel intuitivepharma 2013-12-20 07:36
- FDA: Prasugrel Helmut 2013-12-20 13:46
- FDA: Prasugrel intuitivepharma 2013-12-24 06:38
- FDA: Alternative approaches… Helmut 2013-12-24 14:15
- FDA: Alternative approaches… intuitivepharma 2013-12-26 05:11
- FDA: RTR Helmut 2013-12-26 14:35
- FDA: RTR intuitivepharma 2013-12-31 05:34
- FDA: RTR meghalvakil20 2015-07-23 16:32
- WayBack Machine Helmut 2015-07-23 16:58
- WayBack Machine meghalvakil20 2015-07-23 17:03
- Old stuff Helmut 2015-07-23 17:28
- WayBack Machine meghalvakil20 2015-07-23 17:03
- WayBack Machine Helmut 2015-07-23 16:58
- FDA: RTR Helmut 2013-12-26 14:35
- FDA: Alternative approaches… intuitivepharma 2013-12-26 05:11
- FDA: Alternative approaches… Helmut 2013-12-24 14:15
- FDA: Prasugrel intuitivepharma 2013-12-24 06:38
- FDA: Prasugrel Helmut 2013-12-20 13:46
- FDA: Prasugrel intuitivepharma 2013-12-20 07:36
- EMA: parent whenever possible ElMaestro 2013-09-20 19:35
- EMA: Sirolimus product-specific GL luvblooms 2013-11-19 13:00
- EMA vs. Russia Helmut 2013-09-20 19:21
- EMA: parent whenever possible mittyri 2013-09-20 14:55
- EMA: parent whenever possible Ohlbe 2013-09-20 13:52
- EMA: parent whenever possible Helmut 2013-09-20 12:53
- EMA: parent whenever possible cr.maroj 2013-09-20 10:14
- EMA: parent whenever possible Helmut 2013-09-20 09:02
- Bioequivalence Recommendations for Specific Products Ohlbe 2013-09-19 11:45
